Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is BIO's Director for Health Communications, where he handles communications on public policy issues affecting members of BIO's health and emerging company sections. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He has a Master's degree in Public Relations and Corporate Communications from Georgetown University.

Latest Posts

Report Finds Increasing Number of 340B Hospitals Provide Minimal Charity Care

A new report released yesterday by the Alliance for Integrity and Reform of 340B (AIR340B), of which BIO is a member, found a dramatic decline in charity care provided by 340B hospitals in 2014, which was the first year of coverage expansion under the Affordable Care Act. The report found that over a third (37 percent) provided charity care representing less than 1 percent of total patient costs – far higher than the 24 percent Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Immune Deficiency Foundation: Medicare’s “one size fits all” drug demo is wrong for seniors with rare and chronic diseases

medical_research

Writing yesterday in The Hill, Immune Deficiency Foundation President Marcia Boyle explains the potential harm posed to patients by the recently proposed Medicare Part B demonstration: While CMS’ intent is to save money, the results of this demonstration stand to severely impact patients who rely on Medicare. The reduction in reimbursement will force many providers to stop offering the most clinically effective treatments, leaving patients with two options: forego prescribed therapies or travel to more expensive Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Report: Low Compliance with ACA Charity Care Requirements among 340B Hospitals

Earlier this week, the Alliance for Integrity and Reform of 340B, of which BIO is a member, released a new report examining hospitals’ compliance with the charity care requirements of the Affordable Care Act (ACA). The report found that large numbers of both 340B and non-340B hospitals are not complying with protections contained in the ACA for low-income patients, such as rules designed to ensure they are made aware of a hospital’s charity care program Read More >

Health  |  Leave a comment  |  Email This Post
Tags: ,

Points to Consider about the Center for American Progress Prescription Drug Discussion

health care, medicine

This afternoon, the Center for American Progress (CAP) Action Fund hosted an obviously one-sided discussion on prescription drug pricing. Below are some key questions and points to consider in this important debate that you likely didn’t hear about at the CAP event: Prescription Drugs Only Small Part of Overall Health Spending: Despite the increasingly shrill rhetoric on this issue, the fact remains that prescription drugs are only a small fraction of total health expenditures in Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Facing growing pressure, N.Y. insurers agree to lift restrictions on hepatitis c therapies

Wall Street Journal

Last week, we wrote about the mounting evidence of insurer discrimination and coverage denials for patients with certain high-cost health conditions such as HIV and hepatitis C. In many cases, insurers have been denying new hepatitis C treatments to patients unless their livers showed signs of severe damage – despite guidelines from major medical societies recommending the drugs for nearly all hepatitis C patients. Today, the Wall Street Journal reported some good news for hepatitis Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,